These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32930969)

  • 1. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data.
    Willis M; Asseburg C; Slee A; Nilsson A; Neslusan C
    Diabetes Ther; 2020 Nov; 11(11):2657-2676. PubMed ID: 32930969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.
    Willis M; Nilsson A; Kellerborg K; Ball P; Roe R; Traina S; Beale R; Newell I
    Diabetes Ther; 2021 Jan; 12(1):313-328. PubMed ID: 33263893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
    Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
    Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
    Fernandez-Fernandez B; Fernandez-Prado R; Górriz JL; Martinez-Castelao A; Navarro-González JF; Porrini E; Soler MJ; Ortiz A
    Clin Kidney J; 2019 Jun; 12(3):313-321. PubMed ID: 31198532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Jardine MJ; Mahaffey KW; Neal B; Agarwal R; Bakris GL; Brenner BM; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Xie J; Zhang H; Zinman B; Desai M; Perkovic V;
    Am J Nephrol; 2017 Dec; 46(6):462-472. PubMed ID: 29253846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
    Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M;
    Am J Kidney Dis; 2023 Jul; 82(1):84-96.e1. PubMed ID: 36889425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
    Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.
    Yi TW; Atiquzzaman M; Zheng Y; Smyth B; Jardine M; Levin A
    Can J Kidney Health Dis; 2022; 9():20543581221145068. PubMed ID: 36578697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.
    Chen AX; Fletcher R; Neuen BL; Neal B; Arnott C
    Diabetes Obes Metab; 2024 Jul; ():. PubMed ID: 39036974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.
    Durkin M; Blais J
    Diabetes Ther; 2021 Feb; 12(2):499-508. PubMed ID: 33340064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
    Januzzi JL; Mohebi R; Liu Y; Sattar N; Heerspink HJL; Tefera E; Vaduganathan M; Butler J; Yavin Y; Li J; Pollock CA; Perkovic V; Neal B; Hansen MK
    Circulation; 2023 Aug; 148(8):651-660. PubMed ID: 37603600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
    Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
    Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
    Li JW; Arnott C; Heerspink HJL; MBiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ
    J Am Heart Assoc; 2022 Aug; 11(16):e025045. PubMed ID: 35929472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium.
    Jorissen W; Annemans L; Louis N; Nilsson A; Willis M
    Acta Clin Belg; 2022 Dec; 77(6):945-954. PubMed ID: 34957929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial.
    Vaduganathan M; Cannon CP; Jardine MJ; Heerspink HJL; Arnott C; Neuen BL; Sarraju A; Gogate J; Seufert J; Neal B; Perkovic V; Mahaffey KW; Kosiborod MN
    Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38932575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].
    Scheen AJ
    Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
    Wheeler DC; James J; Patel D; Viljoen A; Ali A; Evans M; Fernando K; Hicks D; Milne N; Newland-Jones P; Wilding J;
    Diabetes Ther; 2020 Dec; 11(12):2757-2774. PubMed ID: 32996085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.